KRAS and cancer: Another in vitro study also supported this view, but a diverse mechanistic interpretation suggested that after treatment with KRAS (G12C) inhibitors, some cancer cells were in a stationary state with low KRAS activity, while others were equipped to resume proliferation due to the synthesis of new KRAS (G12C)177,232.